FDA-approved drug kills cancer cells in lab by disrupting cellular recycling
Researchers from VCU Massey Comprehensive Cancer Center recently demonstrated that the inhibition of glucosylceramide synthase (GCS) can cause death in cancer cells that is independent of changes in pro-death ceramide levels. The findings, which were recently published in Cell Death Discovery, showed that using eliglustat, an FDA-approved drug, induced cell death in several cancer cell lines.…
Read original article on Medical Xpress - latest medical and health news stories →Related news
-
Starting with a statin or statin plus ezetimibe to lower LDL led to similar heart outcomes
United Kingdom
-
Single-pill combination helps more patients control hypertension
United Kingdom
-
Nvidia shares tumble as the company says it's investigating CEO Jensen Huang
United States
-
Doxycycline use in early pregnancy associated with higher risk of pregnancy loss
United Kingdom
-
New surface coating could help implants bond better with bone in people with diabetes
United Kingdom
-
Researcher takes a look at relationship between women and guns
United Kingdom
-
Phone app alerts did not increase bystander CPR rates in study of two major population areas
United Kingdom
-
No link discovered between water fluoridation and cognitive decline in older Irish adults
United Kingdom